abacavir/lamivudine / Generic mfg. - LARVOL DELTA

Graft-versus-HIV-reservoir reactivity: Long term HIV remission after allogeneic stem cell transplantation from a donor with active CCR5 (ASH 2025) - "Three years after alloSCT (September 2017), the patientdiscontinued antiretroviral therapy (Raltegravir and Abacavir/Lamivudine). This is the first case of HIV cure via alloSCT from a donor with active CCR5 and provides compellingevidence that "graft-versus-reservoir" reactivity is the key driver of viral reservoir clearance.For alloSCT recipients living with HIV and their caregivers, these data demonstrate the possibility of HIVcure even when no HIV resistant (CCR5 Δ32/ Δ32) alloSCT donor can be identified. Outside the alloSCTfield, our data builds the underlying rationale for HIV cure strategies based on effective viral reservoirreductions."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Human Immunodeficiency Virus • Immunology • Infectious Disease • Transplantation • CCR5 • CD4 • CXCR4 • FLT3

Advanced coronary artery disease in a low-risk HIV patient – a case for early statin intervention (EACS 2025) - "His antiretroviral regimen initially was Kivexa and Efavirenz, which was then switched to Atripla in 2020 and switched to Descovy and Efavirenz in 2022. This case reinforces the inadequacy of relying solely on traditional risk scores for cardiovascular risk assessment in People Living With HIV(PLWH). Chronic inflammation and endothelial dysfunction associated with HIV infection may drive atherosclerosis independently of classical risk factors. In alignment with the REPRIEVE study outcomes, the BHIVA now recommends initiating statins in PLWH based on Q-Risk, advocating for early, primary preventive cardiovascular management in this population."

Clinical • Metastases • Human Immunodeficiency Virus • Infectious Disease • CD4

Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease in ART-Naïve People Living with HIV Initiating DTG/ABC/3TC vs. BIC/FTC/TAF: A 96-Week Analysis from a Mexican Cohort (EACS 2025) - "Clinicians should weigh these metabolic risks when selecting ART regimens, particularly for PLHIV with risk factors for liver disease. Larger studies with extended follow-up are needed to validate these results and elucidate underlying mechanisms."

Human Immunodeficiency Virus • Infectious Disease

Breastfeeding on ART and a closer look at drug transfer to HIV-exposed uninfected infants. (PubMed, Sci Rep) - "Maternal ART regimens included abacavir/lamivudine (n = 2), tenofovir alafenamide/emtricitabine (n = 1) or tenofovirdisoproxil/emtricitabine (n = 5) in combinations with rilpivirine (n = 3) (RPV), dolutegravir (n = 2) (DTG), raltegravir (n = 1), darunavir/ritonavir (n = 1), or nevirapine (n = 1). Given this variability and the potential for drug accumulation in individual cases, maternal therapeutic drug monitoring should be considered to identify elevated levels early on. In such situations, infant monitoring tailored to the individual may also be warranted."

Journal • Retrospective data • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Neutropenia

No evidence of an effect of the M184I/V on the doravirine/lamivudine/tenofovir switch efficacy in people living with HIV. (PubMed, AIDS) - "Among PLWHIV with antiretroviral experience, there was no evidence that switching to doravirine + lamivudine plus tenofovir affected short-term treatment response in individuals harboring HIV M184I/V mutations."

Journal • Human Immunodeficiency Virus • Infectious Disease

Unmasking Tacrolimus Toxicity due to the Hacked Liver System. (PubMed, Ther Drug Monit) - "This case highlights the importance of reviewing potential drug interactions before prescribing or dispensing drugs."

Journal • Anorexia • Candidiasis • Diabetes • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Pain • Transplantation

No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial). (PubMed, BMC Infect Dis) - "Continuing or discontinuing abacavir for 48 weeks was associated with modest gains in weight that did not differ between groups. Similarly, fat distribution, or metabolic parameters were comparable between groups."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Juan A. Arnaiz | N=150 ➔ 0 | Unknown status ➔ Withdrawn

Enrollment change • HEOR • Trial withdrawal • Human Immunodeficiency Virus • Infectious Disease • CD4

Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice. (PubMed, Commun Biol) - "The LA-ART treatment contains nanoformulated dolutegravir, lamivudine, abacavir, and rilpivirine combinations, and the HIV-1 excision treatment is CRISPR-Cas9 targeting the HIV-1-LTR-gag. These define viral rebound in the dual-treated hu-mice. The data underscores the limited role of CRISPR excision in generating these rebound HIV-1 mutants from dual-treated hu-mice."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease

Ensuring access to essential HIV medicines, strengthening workforce capacity, and driving innovation (IAS-HIV 2025) - "Priority was given to first-line ARVs (ABC/3TC), Nevirapine, Cotrimoxazole (CTX), and Hydrochlorothiazide (HCTZ) for aging HIV patients in rural areas.LESSONS LEARNED: 1. This ongoing project highlights the importance of leveraging innovation to optimize processes and adapt practices to the unique challenges of rural and hard-to-reach areas. Tailored tools and training ensure the consistent supply of essential commodities, strengthening the management of HIV and related ailments. As the initiative progresses from 2022 to 2028, continued monitoring will provide insights to sustain and scale these improvements in underserved communities."

Human Immunodeficiency Virus • Infectious Disease

Assessing the effect of co-administration of Rifapentine with Dolutegravir on viral load suppression among recipients of care on tuberculosis preventive therapy in Delta, Ekiti and Osun States (IAS-HIV 2025) - "Dolutegravir (DTG) forms part of the adult first line regimens in combination with Tenofovir/Lamivudine as TLD or Abacavir/Lamivudine as ALD. Co-administration of 3-HP with Dolutegravir-based regimens did not have negative impact on viral load suppression rates in the absence of Dolutegravir dosage adjustment."

Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases • Tuberculosis

Comprehensive Cardiovascular Risk Profiling in People Living with HIV: Insights from the Japanese Adverse Drug Event Report Database. (PubMed, AIDS Res Hum Retroviruses) - "ART regimen classes (e.g., integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors) and backbone therapies [e.g., abacavir (ABC)/lamivudine] were included in the analysis. Our findings underscore a potentially heightened cardiovascular risk associated with ABC, particularly in older PLWH or those with diabetes. These results highlight the need to consider individual CVD risk profiles when selecting ART regimens and reinforce the importance of ongoing pharmacovigilance to guide safer, more personalized treatment strategies worldwide."

Adverse events • Journal • Cardiovascular • Diabetes • Dyslipidemia • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders

Drug resistance mutations and phylogenetic analysis of HIV-1 subtypes B and F from mothers and children with vertical transmission. (PubMed, BMC Infect Dis) - "Differences in mutation profiles and antiretroviral resistance for NRTI and NNRTI drug classes were observed in half of the mother-child pairs, emphasising the importance of individualised therapeutic strategies."

Journal • Human Immunodeficiency Virus • Infectious Disease

Incidence of Metabolic syndrome in people with HIV without experienCe to antiretroviral Therapy who start doLutegravir based-regimen compared with bictegrAvir based-regimeN after 48 weeks (MICTLAN trial). (PubMed, AIDS) - "Incidence of MetS among PWH receiving an INSTI-based regimen was high, with no difference between BIC/TAF/FTC and DTG/ABC/3TC groups. Age, overweight and elevated visceral fat at baseline were all associated with MetS."

Journal • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Obesity

Dolutegravir/Abacavir/Lamivudine in Acute HIV-1 Results in Rapid Suppression and Restoration of CD4 T-cell Subsets Without Accelerated Decay of Latent HIV-1. (PubMed, Open Forum Infect Dis) - "Thirty-four participants required rapid HLA-B*57 testing at screening; 97% resulted ≤24 hours, and 71% started ART ≤24 hours. Integrase-based ART during acute HIV-1 resulted in brisk viral suppression, preservation of CD4+ T-cell subsets, and decline in resting CD4+ T-cell infection."

Clinical • Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4 • CD8 • HLA-B

Galactorrhea and Headache in an 18-Year-Old Transfeminine Youth: A Case Report (ESPE-ESE 2025) - "Medical History The patient was diagnosed with HIV at 15 years of age and has been on antiretroviral therapy (atazanavir, ritonavir, abacavir/lamivudine)...She has a history of PTSD due to sexual assault and MDD, managed with escitalopram (10 mg/day) and trazodone (50 mg/day as needed)...Later, she purchased 17β-estradiol and cyproterone acetate online, following advice from a senior acquaintance, and intermittently used intramuscular hormones advertised online, including estradiol benzoate (3 mg) and progesterone (50 mg)...Conclusion This case highlights the risks of self-prescribed hormone use in transfeminine youth, emphasizing the need for medical supervision to prevent endocrine complications. Accessible care and regular follow-up are crucial for safer outcomes."

Case report • Clinical • Human Immunodeficiency Virus • Infectious Disease • Pain • Post-traumatic Stress Disorder • CD4

Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms. (PubMed, Pediatr Infect Dis J) - "Twenty-eight Thai children were enrolled and received ABC/3TC-DT plus pediatric dolutegravir-DT once daily. ABC and 3TC exposures were within target ranges across WBs. These data supported current ABC/3TC-DT WHO-weight band dosing guidance for young children in Thailand."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Re-Examining InSTI Effects on Weight Gain Among Treatment-Naive People With HIV in North America (CROI 2025) - "Results Among 32,962 included individuals, median baseline age and BMI were 41 years and 25.4 kg/m2, respectively; 84% were male, and 45% were Black; 10,406 started an INSTI, 13,500 an NNRTI, and 9,056 a PI; and 72% initiated on TDF/FTC, 12% ABC/3TC, and 11% TAF/FTC. These findings suggest that the previously reported differences in weight gain between ART regimens may not be entirely explained by EFV's weight-suppressive effects or its coformulation with TDF. Additionally, other agents, such as non-EFV NNRTIs and EVG/c, may also have weight-suppressive properties."

Human Immunodeficiency Virus • Infectious Disease • CD4

Alternative Dosing of ABC/3TC Dispersible Tablets to Align With Dolutegravir Dosing in Neonates (CROI 2025) - "Methods The 'PETITE' study was a phase I/II, open-label, single arm, PK and safety trial of ABC/3TC-DT (120:60mg, double-scored) and lopinavir boosted with ritonavir (40:10 mg) granules in HIV-exposed term neonates in Tygerberg hospital, South Africa. Conclusions Giving 30/15 mg of ABC/3TC every 48 hours for the first 14 days of life; then daily was predicted to maintained target drug exposures comparable to young children. This dosing schedule should align with the proposed DTG regimen in term neonates during the first month of life."

Human Immunodeficiency Virus • Infectious Disease • Pediatrics

New developments in antiretroviral therapy strategies to improve clinical management of neonates and young infants with HIV. (PubMed, Curr Opin HIV AIDS) - "Studies are ongoing with regards to dolutegravir in various formulations. Long-acting antiretroviral therapy and broadly neutralizing antibodies are currently being studied in neonates and young infants. Addressing maternal clinical and psychosocial health and is a key factor in ensuring infants achieve viral suppression and decreased morbidity."

Journal • Human Immunodeficiency Virus • Infectious Disease

Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study. (PubMed, Medicine (Baltimore)) - P3 | "Switching to B/F/TAF from DTG/ABC/3TC was associated with continued high rates of virologic suppression up to week 168, with no treatment-emergent resistance. B/F/TAF was well tolerated throughout the study period."

Clinical • Head-to-Head • Journal • P3 data • Human Immunodeficiency Virus • Infectious Disease • CD4

Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms. (PubMed, Pediatr Infect Dis J) - "Twenty-eight Thai children were enrolled and received ABC/3TC-DT plus pediatric dolutegravir-DT once daily. ABC and 3TC exposures were within target ranges across WBs. These data supported current ABC/3TC-DT WHO-weight band dosing guidance for young children in Thailand."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

HIV-1 DNA Genotypic Drug Resistance Testing Guides Antiretroviral Therapy in Patients with Low-Level Viremia. (PubMed, AIDS Res Hum Retroviruses) - "The primary resistance mutations observed for nucleoside reverse transcriptase inhibitor (NRTI) were against abacavir, lamivudine, and emtricitabine. For non-NRTI, the primary DRMs were associated with efavirenz and nevirapine...The ART-unchanged case showed progressive treatment failure with drastic increase of plasma HIV-1 RNA and whole blood HIV-1 DNA. For patients with LLV, HIV-1 DNA genotypic drug resistance testing directed ART regimen considerations are highly recommended for achieving viral suppression."

Journal • Human Immunodeficiency Virus • Infectious Disease

No impact of the M184I/V mutation on the efficacy of tenofovir or abacavir+lamivudine+doravirine in HIV treatment‐experienced people (HIV-Glasgow 2024) - "Baseline characteristics of the participants on tri-therapy according to the presence or not of M184V/I at baseline among switch participants (10 imputed datasets) M184V/I at baseline M184V/I at baseline Characteristic No (n = 293) n/N (%) or median (IQR) Yes (n = 45) n/N (%) or median (IQR) p-value Gender 0.3138 Male 191/293 (65.2) 33/45 (73.3) Female 102/293 (34.8) 12/45 (26.7) Viral subtype 0.5998 B 158/293 (53.9) 28/45 (62.2) CRF02 59/293 (20.2) 8/45 (17.8) Other non-B 76/293 (25.9) 9/45 (20.0) Nadir CD4 count (cells/mm3) 257 (130−409) 157 (42−318) 0.0246 CD4 count at baseline (cells/mm3) 620 (467−846) 616 (421−910) 0.9044 Doravirine co-treatment 0.5539 3TC+TDF 268/293 (91.5) 43/45 (95.6) 3TC+ABC 25/293 (8.5) 2/45 (4.4) GSS with doravirine (Stanford) 3.0 (3.0−3.0) 1.5 (1.0−2.0) <.0001 GSS with doravirine (ANRS) 3.0 (3.0−3.0) 2.0 (1.5−2.0) <.0001 Number of NNRTI mutations at baseline 0 (0−1) 1 (0−2) <.0001 Log zenith plasma HIV-1 RNA (log10 copies/ml) 4.9..."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Antiretroviral therapy in pregnancy in England in 2019‐2022: common regimens and treatment modifications (HIV-Glasgow 2024) - "Among pregnancies conceived on ART, most common (reported in >5%) first regimens were efavirenz (EFV) + tenofovir disoproxil fumarate (TDF) + emtricitabine (FTC) (13.5% [267/1974]), rilpivirine (RPV) +TDF+FTC (11.6% [228/1974]), darunavir/ritonavir (DRV/r) +TDF+FTC (8.0% [158/1974]), dolutegravir (DTG) + lamivudine (3TC) + abacavir (ABC) (7.7% [152/1974]), and raltegravir (RAL) +TDF+FTC (6.4% [127/1974]). Where ART was initiated during pregnancy (55.7% [234/420] diagnosed antenatally), median gestational age at start was 15 weeks (IQR 12–19); most common first regimens were RAL+TDF+FTC (17.7% [75/423]), DRV/r+TDF+FTC (15.4% [65/423]), atazanavir/ritonavir (ATV/r) +TDF+FTC (12.5% [53/423]), DTG+3TC+ABC (9.2% [39/423]) and DTG+TDF+FTC (8.3% [35/423])...3TC, lamivudine; ABC, abacavir; ATV/c, atazanavir/cobicistat; ATV/r, atazanavir/ritonavir; BIC, bictegravir; DRV/c, darunavir/cobicistat; DRV/r, darunavir/ritonavir; DTG, dolutegravir; EFV, efavirenz; EVG/c,..."

Human Immunodeficiency Virus • Infectious Disease